Funding for this research was provided by:
Academy of Finland (287287, 294054, 319257, 267471, 308315)
Emil Aaltosen Säätiö (Project funding)
Päivikki ja Sakari Sohlbergin Säätiö (Project funding)
Jane ja Aatos Erkon Säätiö (Project funding)
Received: 25 March 2019
Accepted: 11 July 2019
First Online: 15 August 2019
Ethics approval and consent to participate
: The National Authority for Medicolegal Affairs Finland has approved the study with human embryos (Dnro 1426/32/300/05). The supportive statement from the ethics committee of the Pirkanmaa hospital district Finland allows us to derive and expand hESC-lines from surplus embryos excluded from infertility treatments, and to use the lines for research purposes (R05116). New cell lines were not derived in this study. In mouse studies, all animals were treated in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research using protocols approved and monitored by the Animal Experiment Board of Finland.
: Not applicable.
: The authors declare that they have no competing interests.